Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease and Up to Three Years of an Open-Label Extension With Active Study Treatment

Trial Profile

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease and Up to Three Years of an Open-Label Extension With Active Study Treatment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Gantenerumab (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms SCarlet RoAD
  • Sponsors Roche
  • Most Recent Events

    • 20 Jul 2017 Results (n=797) presented at the Alzheimer's Association International Conference 2017
    • 20 Jul 2017 Results of analysis estimating clinically relevant change and difference thresholds for the clinical dementia rating -sum of boxes using patient data from ADNI, NCT01224106 and NCT01343966 trials presented at the Alzheimer's Association International Conference 2017
    • 20 Jul 2017 Results of first report exploring correlation between vascular pathology at baseline and occurrence of ARIA-E in prodromal AD patients presented at the Alzheimer's Association International Conference 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top